Taencon: The CKBA cream applied for clinical trials for children with vitiligo has received an acceptance letter.

Tiankang announced that its holding subsidiary, Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd., recently received an acceptance notification issued by the National Medical Products Administration, agreeing to accept the application for a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study on the safety, tolerability, efficacy, and pharmacokinetic characteristics of CKBA cream combined with narrow-band ultraviolet B therapy in non-segmental vitiligo patients aged 2-12 years old.